Moderna slips as EU regulator cites more side effects possibly linked to COVID-19 shot

Seeking Alpha2021-08-12
  • Moderna, Inc. has dropped sharply for the second consecutive session as the European drugs regulator pointed to three more conditions developed by a small number of people after receiving the company’s COVID-19 shot.
  • The Pharmacovigilance Risk Assessment Committee (PRAC) of European Medicines Agency (EMA) has started an assessment of Erythema multiforme, nephrotic syndrome, and glomerulonephritis experienced by some recipients of the vaccine.
  • Erythema multiforme is a form of allergic condition on the skin, nephrotic syndrome is a kidney disease affecting protein filtration, and glomerulonephritis affects tiny filters in kidneys.
  • As of July 29, a little over 43.5M doses of Moderna’s COVID-19 vaccine have been used in the region compared to more than 330M doses of the rival vaccine from Pfizer/BioNTech SE.
  • The regulator had requested more information from companies to establish a possible link but did not reveal the number of newly found cases. Moderna (MRNA) was not immediately available for Reuters’ request for comments.

  • The latest findings follow the warnings issued by the EU watchdog in July for messenger-RNA-based COVID-19 shots developed by Moderna (MRNA), Pfizer (PFE)/ BioNTech (BNTX) to indicate the rare cases of heart inflammation linked to the vaccines.

  • After their recent peak, Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX) are all trading lower today.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
4